Business
Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025
Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces it will host an Obesity Portfolio Webinar on April 2, 2025, from 9:00 a.m. – 10:30 a.m. ET.
About this update from Ascletis Pharma, Inc.
[{"type":"text","content":"HONG KONG, March 20, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces it will host an Obesity Portfolio Webinar on April 2, 2025, from 9:00 a.m. – 10:30 a.m. ET.","length":198,"tagName":"p"},{"type":"text","content":"The event will include a detailed discussion on Ascletis' obesity portfolio including exciting data about its potential best-in-class clinical stage GLP-1R biased small molecule agonist, ASC30, for both once daily oral tablet and once monthly subcutaneous injection administration. Jinzi Jason Wu, Ph.D., Founder, Chairman & CEO of Ascletis, and John Gargiulo, MBA, Chief Business Officer of Ascletis, will host Q&A immediately following the presentation.","length":467,"tagName":"p"},{"type":"text","content":"Presentation Date: Wednesday, April 2, 2025","length":48,"tagName":"p"},{"type":"text","content":"Time: 9:00 a.m. – 10:30 a.m. Eastern Time","length":46,"tagName":"p"},{"type":"text","content":"Registration: To access and attend the virtual event, please register HERE.","length":80,"tagName":"p"},{"type":"text","content":"An archived replay of the webcast will be available at the same link HERE for 30 days following the event. If you have any questions, please contact [email protected].","length":182,"tagName":"p"},{"type":"text","content":"About Ascletis Pharma Inc.","length":26,"tagName":"p"},{"type":"text","content":"Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on two therapeutic areas with unmet medical needs from a global perspective: metabolic diseases and viral diseases. Ascletis has multiple clinical stage drug candidates in its R&D pipeline.","length":479,"tagName":"p"},{"type":"text","content":"For more information, please visit www.ascletis.com.","length":52,"tagName":"p"},{"type":"text","content":"Contact：Peter VozzoICR Healthcare443-231-0505 (U.S.)[email protected]","length":85,"tagName":"p"},{"type":"text","content":"Ascletis Pharma Inc. PR and IR teams+86-181-0650-9129 (China)[email protected] [email protected]","length":95,"tagName":"p"},{"type":"image","alt":"Cision","disp...